CD99 and neoplasm: An innovative strategy to reduce fratricide, a major limitation in CAR-T therapy for ALL, has been developed by Anqi Ren et al. By targeting CD99, they discovered that directly transducing the T-ALL Jurkat cell line with the anti-CD99 single-chain variable fragment (scFv) 12E7 prompted the self-elimination of tumor cells, providing a promising solution to enhance CAR-T efficacy in T-ALL [107].